According to Margaret Chan, the Director-General of the WHO, "A profit-driven industry does not invest in products for markets that cannot pay."
The head of the World Health Organization (WHO) on Monday castigated the pharmaceutical industry for failing to develop a vaccine for Ebola over the some 40 years that the virus has threatened West Africa.
Speaking in Cotonou, Benin, Margaret Chan, the director general of the WHO, wondered rhetorically why clinicians are “still empty-handed, with no vaccines and no cure” for Ebola, even though the disease first appeared some four decades ago.
The answer, said Chan, is at least in part that “Ebola has historically been confined to poor African nations.” She lambasted drug manufacturers for not taking an interest in an Ebola vaccine until the disease became a threat to non-African countries, including the U.S.
Complete report on TIME: http://ti.me/1tWX1YY
Health Equity Adjustments in Medicare HVBP Program Will Benefit Safety Net Hospitals, Study Says
March 29th 2024Medicare’s upcoming health equity adjustment in the Hospital Value-Based Purchasing (HVBP) program will reduce disproportionate penalization among safety net hospitals and those serving high proportions of Black patients, according to a recent study.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Approves Ravulizumab-cwvz for Rare Autoimmune Disease
March 28th 2024Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.
Read More